Clinical trials: Obstructive Pulmonary Diseases
COPD
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
- Trial name
- NCT01972776
- Testing
- QBM076
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Asthma
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1…
- Trial name
- NCT00837967
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Asthma
Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway
The addition of an inhaled long-acting beta-adrenergic agonist to an inhaled glucocorticosteroid improves disease control in persistent asthma.
- Trial name
- NCT01231230
- Testing
- fluticasone, Salmeterol, fluticasone/salmeterol
- Volunteers
- 14 people
- Sponsor
- University of Miami
Pulmonary Disease, Chronic Obstructive
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic…
- Trial name
- NCT01387230
- Testing
- GSK573719
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 206 people
- Sponsor
- GlaxoSmithKline
Asthma
Dose Ranging Study for Indacaterol in Japanese Asthma Patients
This study was designed to provide data about the safety and efficacy of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese asthma patients so that an optimal dose, or doses, could be chosen for testing in later studies.
- Trial name
- NCT00403754
- Testing
- Indacaterol, Salmeterol
- Where
- 8 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
This study is a phase III clinical study to assess the efficacy and safety of Revefenacin inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to placebo in a population of Chinese subjects…
- Trial name
- NCT05046795
- Testing
- Revefenacin 175 mcg in 3 ML Inhalation Solution
- Where
- 35 sites in China
- Volunteers
- 258 people
- Sponsor
- Mylan Pharma UK Ltd.
Asthma
Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).
- Trial name
- NCT00337675
- Testing
- montelukast sodium
- Volunteers
- 1,771 people
- Sponsor
- Organon and Co
Nasal Polyps
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years)…
- Trial name
- THUNDER (NCT03681093)
- Testing
- Fevipiprant 150 mg, Fevipiprant 450 mg
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Asthma, Allergic Rhinitis
Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
This study will provide the clinicians guidance on the safest combination of inhaled and nasal corticosteroids for children with mild asthma and allergic rhinitis respectively; however, one safety concern is that these products…
- Trial name
- NCT01550471
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- West Penn Allegheny Health System
Asthma
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
This is a US study comparing the efficacy and safety of BDA MDI [Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)] with AS [Albuterol Sulfate] MDI, both are administered as needed for up to 12 months.
- Trial name
- NCT05505734
- Testing
- BDA MDI, AS MDI
- Where
- 61 sites in United States
- Volunteers
- 2,516 people
- Sponsor
- Bond Avillion 2 Development LP
Chronic Obstructive Pulmonary Disease, Asthma
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
Goal: to to examine the formation of postvaccination immunity and evaluate the therapeutic effect of bacterial vaccines in patients with inflammation diseases of bronchopulmonary system.
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Pneumococcal Infections
- Trial name
- NCT02787863
- Testing
- Prevenar-13, Pneumo-23
- Where
- 2 sites in Russia
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Mikhael Petrovich Kostinov
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00891462
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 561 people
- Sponsor
- AstraZeneca
Asthma
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
To evaluate the dose-response of different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate, on lung function and other clinical outcomes and to identify the optimal dose(s) with regard to…
- Trial name
- FLASH (NCT03086460)
- Testing
- CHF 1531 pMDI, Formoterol Inhalation Solution
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.
- Trial name
- NCT03663569
- Testing
- Spiolto® Respimat®
- Where
- 388 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 4,819 people
- Sponsor
- Boehringer Ingelheim
Asthma
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI…
- Trial name
- NCT02794480
- Testing
- ELLIPTA DPI, GSK MDI, AZ MDI
- Where
- 20 sites in United States
- Volunteers
- 324 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
This is a comparative bioavailability study to compare the pharmacokinetics and pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler in…
- Trial name
- NCT01494610
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.